Clinical trial
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
NCT00088595 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00088595 |
|---|---|
| Title | Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors |
| Official title | An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoid Tumors |
| Intervention type | Drug |
| Interventions | Pasireotide (SOM230) |
| Enrollment | 45 |
| Start date | Jan 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Aug 2, 2004 |
| Last update posted | Jun 4, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: